Jubilant and Cyclopharm mutually agree to terminate term sheet for Technegas licensing agreement

Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant DraxImage Inc (JDI) and Cyclopharm (CYC) have mutually terminated their previously announced term sheet for exclusive commercial rights of Technegas in the US market. Both parties have agreed to discuss potential commercial opportunities once CYC obtains USFDA approval for Technegas.

Jubilant Life Sciences is engaged in manufacturing and supplying of application program interface (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and life science ingredients like advance intermediates (pyridine and picoline), fine ingredients (pyridine and picoline derivatives for pharmaceuticals and others, crop science ingredients (pyridine and picoline derivatives for agrochemicals), nutritional products (vitamin B3- niacinamide and niacin, choline chloride and premixes) and life science chemicals (acetyls).